Sugi Predict

Sugi Predict / Compounds / SCHEMBL4960665

SCHEMBL4960665

SCHEMBL4960665

CC(NC(=O)OC(C)(C)C)c1cccc(N)c1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 3/20 0.46
▸ CTSS P25774 1/20 0.43
▸ MAPKAPK2 P49137 1/20 0.41
▸ GABRB1 P18505 1/20 0.41
▸ GABRB2 P47870 1/20 0.41
▸ CYP2D6 P10635 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ RPS6KB1 P23443 1/20 0.40
▸ AAK1 Q2M2I8 1/20 0.40
▸ KLK5 Q9Y337 1/20 0.40
▸ ADRB2 P07550 1/20 0.40
▸ ADRB1 P08588 1/20 0.40
▸ ADRB3 P13945 1/20 0.40
▸ GLS O94925 2/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31226578 1.00 CTSK (0.46) CTSKCTSSMAPKAPK2GABRB1GABRB2
SCHEMBL22851708 1.00 CTSK (0.46) CTSKCTSSMAPKAPK2GABRB1GABRB2
SCHEMBL6487442 0.84 CTSK (0.47) CTSKCTSSMAPKAPK2GABRB1GABRB2
SCHEMBL2008100 0.84 CTSK (0.47) CTSKCTSSMAPKAPK2GABRB1GABRB2
SCHEMBL781623 0.84 CTSK (0.47) CTSKCTSSMAPKAPK2GABRB1GABRB2
SCHEMBL19479409 0.84 CTSK (0.47) CTSKCTSSGABRB1GABRB2
SCHEMBL11065297 0.83 CTSK (0.50) CTSKCTSSGABRB1GABRB2KLK5
SCHEMBL16791251 0.83 HPGDS (0.49) CTSKCTSSGABRB1GABRB2KLK5
SCHEMBL9261922 0.83 CTSK (0.50) CTSKCTSSGABRB1GABRB2KLK5
SCHEMBL2233904 0.83 CTSK (0.50) CTSKCTSSGABRB1GABRB2KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192644-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
US-20230192644-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 — — US disclosed
EP-4153175-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE Dana-Farber Cancer Institute, Inc. (US) 2023-03-29 — — EP disclosed
WO-2021236885-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-11-25 — — WO disclosed
EP-2888262-B1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS HOFFMANN LA ROCHE (CH) 2018-12-19 — — EP disclosed
US-9334278-B2 Pyrrolo[2,3-B]pyrazines as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-05-10 — — US disclosed
US-20150218170-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-08-06 — — US disclosed
US-7470815-B1 Selective neuronal nitric oxide synthase inhibitors NORTHWESTERN UNIVERSITY (US) 2008-12-30 — — US disclosed
US-20050159363-A1 Selective neuronal nitric oxide synthase inhibitors SILVERMAN RICHARD B (US) 2005-07-21 — — US disclosed
EP-0798292-B1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) 2004-11-03 — — EP disclosed
US-6803486-B2 PEPTIDOMIMETIC; N-AMINOBUTYL-N'-NITROGUANIDINE DERIVATIVES NORTHWESTERN UNIVERSITY 2004-10-12 — — US disclosed
US-20030119751-A1 Selective neuronal nitric oxide synthase inhibitors NORTHWESTERN UNIVERSITY 2003-06-26 — — US disclosed
US-6534546-B1 Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-18 — — US disclosed
US-6369070-B1 Methods for inhibiting mrp1 ELI LILLY AND COMPANY 2002-04-09 — — US disclosed
CN-1075808-C Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 2001-12-05 — — CN disclosed
CN-1310169-A Anils with nitric oxide synzyme inhibiting function SHUGAI SEIYAKU K K (JP) 2001-08-29 — — CN disclosed
CN-1172473-A Aniline derivatives having nitric oxide synthase inhibitory activity CHUGAI PHARMACEUTICAL CO LTD (JP) 1998-02-04 — — CN disclosed
EP-0798292-A1 ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY Chugai Seiyaku Kabushiki Kaisha (JP) 1997-10-01 — — EP disclosed
WO-1997020822-A1 QUINAZOLIN-2,4-DIAZIRINES AS NPY RECEPTOR ANTAGONIST NOVARTIS AG (CH) 1997-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159363-A1 Selective neuronal nitric oxide synthase inhibitors NOS1, NOS3, NOS2 CTSK 2298/4885CTSS 1457/4885MAPKAPK2 727/4885
US-20150218170-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS SYK, ZAP70, BTK CTSK 1059/4885CTSS 1237/4885MAPKAPK2 731/4885
US-20030119751-A1 Selective neuronal nitric oxide synthase inhibitors NOS1, NOS3, NOS2 CTSK 2298/4885CTSS 1457/4885MAPKAPK2 727/4885
US-20230192644-A1 PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE IKZF2, IKZF1, NUTF2 CTSK 2721/4885CTSS 1967/4885MAPKAPK2 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.